Company Description
Artivion, Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide.
The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.
It offers E-xtra design engineering systems for the treatment of aortic vascular diseases; E-nside, an off-the-shelf stent graft for the treatment of thoraco-abdominal disease; E-vita THORACIC 3G for the endovascular treatment of thoracic aortic aneurysms; E-ventus BX, a balloon-expandable peripheral stent graft for the endovascular treatment of renal and pelvic arteries; E-liac to treat aneurysmal iliac arteries, and aneurysmal iliac side branches; and E-tegra, a stent graft system for the treatment of infrarenal abdominal aortic aneurysms.
In addition, the company offers synthetic vascular grafts for use in open aortic and peripheral vascular surgical procedures; PerClot, an absorbable powdered hemostat for use in surgical procedures; cardiac laser therapy products for angina treatment; CryoVein femoral vein and CryoArtery femoral artery vascular preservation services; On-X prosthetic aortic and mitral heart valves and the On-X ascending aortic prosthesis; CarbonAid CO2 diffusion catheters and Chord-X ePTFE sutures for mitral chordal replacement; and ascyrus medical dissection stents, as well as pyrolytic carbon coating services to medical device manufacturers.
It serves physicians, hospitals, and other healthcare facilities, as well as cardiac, vascular, thoracic, and general surgeons.
The company was formerly known as CryoLife, Inc. and changed its name to Artivion, Inc. in January 2022.
Artivion, Inc. was incorporated in 1984 and is headquartered in Kennesaw, Georgia.
| Country | United States |
| Founded | 1984 |
| IPO Date | Feb 11, 1993 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 1,500 |
| CEO | James Patrick Mackin |
Contact Details
Address: 1655 Roberts Boulevard N W Kennesaw, Georgia 30144 United States | |
| Phone | (770) 419-3355 |
| Website | artivion.com |
Stock Details
| Ticker Symbol | AORT |
| Exchange | NYSE |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000784199 |
| CUSIP Number | 228903100 |
| ISIN Number | US2289031005 |
| Employer ID | 59-2417093 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| James Patrick Mackin | Chairman, President and Chief Executive Officer |
| Lance A. Berry CPA | Executive Vice President of Finance, Chief Operating Officer and Chief Financial Officer |
| Amy D. Horton CPA | Vice President and Chief Accounting Officer |
| Jean F. Holloway Esq. | Senior Vice President, General Counsel, Chief Compliance Officer and Corporate Secretary |
| John E. Davis | Senior Vice President and Chief Commercial Officer |
| Matthew A. Getz | Vice President of Human Resources and Chief Human Resources Officer |
| Dr. Marshall S. Stanton M.D. | Senior Vice President of Clinical Research and Chief Medical Officer |
| Dr. Robert C. Thomson | Vice President of Research and Development |
| Florian Tyrs | Vice President of Global Operations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 1, 2024 | ARS | Filing |
| Apr 1, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 1, 2024 | DEF 14A | Other definitive proxy statements |
| Mar 21, 2024 | PRE 14A | Other preliminary proxy statements |
| Mar 15, 2024 | 144 | Filing |
| Mar 14, 2024 | 144 | Filing |
| Mar 12, 2024 | 144 | Filing |
| Mar 11, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Mar 1, 2024 | S-3ASR | Automatic shelf registration statement of securities of well-known seasoned issuers |
| Feb 23, 2024 | 10-K | Annual Report |